Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program.

MLA

Park, Se Hoon, et al. “Avelumab First-Line Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Real-World Results from a Korean Expanded Access Program.” Frontiers in Oncology, vol. 14, June 2024, p. 1403120. EBSCOhost, https://doi.org/10.3389/fonc.2024.1403120.

APA

Park, S. H., Shin, S. J., Rha, S. Y., Beom, S.-H., Seo, H. K., Keam, B., Kim, M., Hong, Y.-H., Yoon, S., & Lee, J.-L. (2024). Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program. Frontiers in Oncology, 14, 1403120. https://doi.org/10.3389/fonc.2024.1403120

Chicago

Park, Se Hoon, Sang Joon Shin, Sun Young Rha, Seung-Hoon Beom, Ho Kyung Seo, Bhumsuk Keam, Miso Kim, Yoon-Hee Hong, Shinkyo Yoon, and Jae-Lyun Lee. 2024. “Avelumab First-Line Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Real-World Results from a Korean Expanded Access Program.” Frontiers in Oncology 14 (June): 1403120. doi:10.3389/fonc.2024.1403120.